
Urihold 25mg Tablet ER
Marketer
Aristo Pharmaceuticals Pvt Ltd
Salt Composition
Mirabegron (25mg)
Overview Urihold 25mg Tablet ER
Vesicol 25mg Extended-Release Tablets alleviate overactive bladder symptoms such as urinary frequency, urgency, and incontinence. This medication promotes bladder muscle relaxation, enhancing urine storage capacity. Always adhere to your physician's prescribed dosage and regimen. Vesicol 25mg ER tablets may be taken with or without food; swallow whole, avoiding crushing or chewing. Discontinue use only under medical supervision, as abrupt cessation may exacerbate symptoms. Complete the prescribed course for optimal therapeutic benefit. Potential side effects include constipation, headache, hypertension, rhinitis, urinary tract infections, tachycardia, and arthralgia. Report any persistent or bothersome side effects to your doctor promptly. Before commencing treatment, disclose all current medications and pre-existing health conditions, including pregnancy or breastfeeding status. Patients with hepatic or renal impairment require close medical monitoring and regular follow-up appointments.
Primary Ingredients of Urihold 25mg Tablet ER
No text provided to rephrase.
Uses of Urihold 25mg Tablet ER
Managing overactive bladder (OAB) symptoms
Major Benefits of Urihold 25mg Tablet ER:
Follow your doctor's instructions precisely regarding the dosage and treatment length for Urihold 25mg Extended-Release Tablets. Ingest the tablet whole; do not alter its form by chewing, crushing, or breaking it. While you can take it with or without food, consistency is key—take it at the same time each day.
Common Side effects of Urihold 25mg Tablet ER:
- Constipation
- Headache
- High blood pressure
- Nasal inflammation
- Urinary tract infection
- Fast heart rate
- Joint pain
How to use Urihold 25mg Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the 25mg extended-release Urihold tablet whole; avoid chewing, crushing, or fracturing it. While consumption with or without food is permissible, consistent daily timing is recommended for optimal results.
How Urihold 25mg Tablet ER works:
Extended-release Urihold 25mg tablets utilize a beta-3 adrenergic agonist mechanism. This activates bladder receptors, resulting in detrusor muscle relaxation and a reduction in urinary urgency, frequency, and incontinence.
SAFETY ADVICE
AlcoholCAUTION
Use caution when drinking alcohol while taking Urihold 25mg Extended-Release tablets. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
Extended-release Urihold 25mg tablets may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Urihold 25mg tablets are likely unsafe for breastfeeding mothers. Available evidence from human studies indicates potential transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Urihold 25mg Extended-Release Tablets.
KidneyCAUTION
Extended-release Urihold 25mg tablets require careful administration in individuals with significant renal impairment. Dosage modification of Urihold 25mg extended-release tablets may be necessary. Physician consultation is advised.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Urihold 25mg Extended-Release tablets, potentially requiring dosage modification. Consult a physician for guidance. Urihold 25mg Extended-Release tablets are contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Urihold 25mg Tablet ER :
Should you forget a Urihold 25mg Extended-Release Tablet, take it immediately. However, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Urihold 25mg Tablet ER
| Label | Value |
|---|---|
| Chemical Category | Anilide-based compound |
| Developing Habits | No. |
| Type of Therapy | Urologic Care |
| Action Category | Beta-3 agonist for bladder control |
